US5364628A
(en)
*
|
1985-05-31 |
1994-11-15 |
Sandoz Ltd. |
Pharmaceutical compositions
|
US5560922A
(en)
*
|
1986-05-30 |
1996-10-01 |
Rutgers, The State University Of New Jersey |
Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
|
GB8626098D0
(en)
*
|
1986-10-31 |
1986-12-03 |
Euro Celtique Sa |
Controlled release hydromorphone composition
|
US4906463A
(en)
*
|
1986-12-22 |
1990-03-06 |
Cygnus Research Corporation |
Transdermal drug-delivery composition
|
US4839174A
(en)
*
|
1987-10-05 |
1989-06-13 |
Pharmetrix Corporation |
Novel transdermal nicotine patch
|
US5026556A
(en)
*
|
1988-11-10 |
1991-06-25 |
Norwich Eaton Pharmaceuticals, Inc. |
Compositions for the transdermal delivery of pharmaceutical actives
|
DE3910543A1
(de)
*
|
1989-04-01 |
1990-10-11 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
|
US5096715A
(en)
*
|
1989-11-20 |
1992-03-17 |
Alko Ltd. |
Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
|
US5240711A
(en)
*
|
1989-11-29 |
1993-08-31 |
Lts Lohmann Therapie-Systeme Gmbh & Co. Kg |
Transdermal therapeutic system comprising as active component buprenorphine
|
DE3939376C1
(fi)
*
|
1989-11-29 |
1991-05-08 |
Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De |
|
US5069909A
(en)
*
|
1990-06-20 |
1991-12-03 |
Cygnus Therapeutic Systems |
Transdermal administration of buprenorphine
|
GB9021674D0
(en)
*
|
1990-10-05 |
1990-11-21 |
Ethical Pharma Ltd |
Transdermal device
|
US5149538A
(en)
*
|
1991-06-14 |
1992-09-22 |
Warner-Lambert Company |
Misuse-resistive transdermal opioid dosage form
|
WO1993014727A1
(en)
*
|
1992-01-31 |
1993-08-05 |
Cygnus Therapeutic Systems |
Transdermal administration of buprenorphine in the form of ion pair complexes
|
US5900250A
(en)
*
|
1992-05-13 |
1999-05-04 |
Alza Corporation |
Monoglyceride/lactate ester permeation enhancer for oxybutnin
|
EP0721348B1
(en)
*
|
1993-09-29 |
1999-09-01 |
Alza Corporation |
Monoglyceride/lactate ester permeation enhancer
|
DE4403709A1
(de)
*
|
1994-02-07 |
1995-08-10 |
Lohmann Therapie Syst Lts |
Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
|
EP0748629A4
(en)
*
|
1994-03-11 |
1997-08-20 |
Sekisui Chemical Co Ltd |
PERCUTANEOUS ABSORPTION PLATTER COMPRISING A MORPHINE ACID ADDED SALT
|
JP2819236B2
(ja)
*
|
1994-05-06 |
1998-10-30 |
日東電工株式会社 |
経皮吸収製剤
|
DE4423850A1
(de)
*
|
1994-07-07 |
1996-01-11 |
Labtec Gmbh |
Transdermales therapeutisches System zur Applikation von Naloxon
|
US5785991A
(en)
*
|
1995-06-07 |
1998-07-28 |
Alza Corporation |
Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
|
US5733571A
(en)
*
|
1995-12-08 |
1998-03-31 |
Euro-Celtique, S.A. |
Transdermal patch for comparative evaluations
|
JPH1036265A
(ja)
*
|
1996-07-19 |
1998-02-10 |
Nitto Denko Corp |
ブプレノルフィン経皮吸収製剤
|
US5968547A
(en)
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
US5919473A
(en)
*
|
1997-05-12 |
1999-07-06 |
Elkhoury; George F. |
Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
|
CA2302754C
(en)
*
|
1997-09-04 |
2011-11-08 |
Novoneuron, Inc. |
Noribogaine in the treatment of pain and drug addiction
|
PT1041987E
(pt)
|
1997-12-22 |
2006-07-31 |
Euro Celtique Sa |
Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
JP2001526229A
(ja)
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク,エス.エイ. |
オピオイド投薬剤形の乱用を防止する方法
|
US6541021B1
(en)
*
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
MXPA01011480A
(es)
*
|
1999-05-13 |
2002-06-04 |
Unihart Corp |
Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.
|
AU785372B2
(en)
*
|
1999-12-16 |
2007-03-01 |
Trident Technologies, Llc |
System and method for extended delivery of a therapeutic agent with its receptor loading dose
|
IL151058A0
(en)
|
2000-02-08 |
2003-04-10 |
Euro Celtique Sa |
Controlled-release compositions containing opioid agonist and antagonist
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
EP2092936B1
(en)
|
2000-02-08 |
2013-03-20 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
KR20080053423A
(ko)
|
2000-07-31 |
2008-06-12 |
니코메드 댄마크 에이에스 |
코 투여용 펜타닐 조성물
|
US6569449B1
(en)
|
2000-11-13 |
2003-05-27 |
University Of Kentucky Research Foundation |
Transdermal delivery of opioid antagonist prodrugs
|
US6682757B1
(en)
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
EP1387673B1
(en)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
DK1390866T3
(da)
|
2001-05-22 |
2010-05-10 |
Euro Celtique Sa |
Beholder og fremgangsmåde til afgivelse af transdermale doseringsformer
|
US8329734B2
(en)
*
|
2009-07-27 |
2012-12-11 |
Afgin Pharma Llc |
Topical therapy for migraine
|
ES2312585T3
(es)
*
|
2001-06-05 |
2009-03-01 |
Ronald Aung-Din |
Terapia contra la migraña por via topica.
|
ATE419039T1
(de)
*
|
2001-07-18 |
2009-01-15 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
RU2004106619A
(ru)
|
2001-08-06 |
2005-07-10 |
Эро-Селтик С.А. (Lu) |
Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US6844438B2
(en)
*
|
2001-08-15 |
2005-01-18 |
Mclean Hospital Corporation |
N-substituted derivatives of morphinan and uses thereof
|
CA2460352C
(en)
*
|
2001-08-17 |
2013-05-14 |
Lavipharm Laboratories Inc. |
Composition and transdermal drug delivery device
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
JP2005528359A
(ja)
*
|
2002-03-20 |
2005-09-22 |
ユーロ−セルティーク エス.エイ. |
うつ病の治療のためのブプレノルフィンの投与方法
|
ES2733051T1
(es)
|
2002-04-05 |
2019-11-27 |
Euro Celtique Sa |
Matriz para liberación sostenida, invariable e independiente de compuestos activos
|
WO2003090729A1
(en)
|
2002-04-23 |
2003-11-06 |
Alza Corporation |
Transdermal analgesic systems with reduced abuse potential
|
US20040033255A1
(en)
|
2002-06-10 |
2004-02-19 |
Baker Carl J. |
Transdermal delivery device disposal system
|
DK1530469T3
(da)
*
|
2002-08-20 |
2009-05-04 |
Euro Celtique Sa |
Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
|
DK1551372T3
(en)
*
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
EP1554290B1
(en)
*
|
2002-10-25 |
2009-09-30 |
Euro-Celtique S.A. |
Analogs and prodrugs of buprenorphine
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
EP1572167B1
(en)
*
|
2002-12-13 |
2008-07-09 |
Euro-Celtique S.A. |
Transdermal buprenorphine dosage regimen for analgesia
|
WO2004054554A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Euro-Celtique S.A. |
Transdermal buprenorphine to treat pain in sickle cell crisis
|
EP1913938A1
(en)
|
2002-12-13 |
2008-04-23 |
Euro-Celtique S.A. |
Transdermal buprenorphine dosage regimen for analgesia
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
EP2319505A1
(en)
*
|
2003-04-30 |
2011-05-11 |
Purdue Pharma L.P. |
Transdermal dosage form comprising an active agent component and an adverse agent component in a ratio from 1:10 up to 10:1
|
US20040236280A1
(en)
*
|
2003-05-22 |
2004-11-25 |
Rice Lisette M. |
Tubular device for insertion into a hollow organ, and method to form same
|
US20070065463A1
(en)
*
|
2003-06-20 |
2007-03-22 |
Ronald Aung-Din |
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
|
AU2004261181B2
(en)
*
|
2003-07-25 |
2009-08-06 |
Euro-Celtique S.A. |
Preoperative treatment of post operative pain
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
EP1677771A2
(en)
*
|
2003-10-30 |
2006-07-12 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
NZ549576A
(en)
|
2004-02-23 |
2010-04-30 |
Euro Celtique Sa |
Abuse resistance opioid transdermal delivery device using microspheres of opiate antagonist
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
LT1765292T
(lt)
|
2004-06-12 |
2018-01-10 |
Collegium Pharmaceutical, Inc. |
Nuo piktnaudžiavimo apsaugotos vaistų formos
|
JP4824963B2
(ja)
*
|
2004-08-12 |
2011-11-30 |
日東電工株式会社 |
貼付材及び貼付製剤
|
JP4745747B2
(ja)
*
|
2004-08-12 |
2011-08-10 |
日東電工株式会社 |
フェンタニル含有貼付製剤
|
DE102004044578A1
(de)
*
|
2004-09-13 |
2006-03-30 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
|
ES2346895T3
(es)
|
2004-10-21 |
2010-10-21 |
Durect Corporation |
Sistemas de administracion transdermica.
|
US8252320B2
(en)
|
2004-10-21 |
2012-08-28 |
Durect Corporation |
Transdermal delivery system for sufentanil
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
WO2006124584A2
(en)
*
|
2005-05-13 |
2006-11-23 |
Alza Corporation |
Multilayer drug delivery system with barrier against reservoir material flow
|
TWI366460B
(en)
|
2005-06-16 |
2012-06-21 |
Euro Celtique Sa |
Cannabinoid active pharmaceutical ingredient for improved dosage forms
|
US20070196456A1
(en)
*
|
2005-09-15 |
2007-08-23 |
Visible Assets, Inc. |
Smart patch
|
CA2642338A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Aveva Drug Delivery Systems |
Adhesive preparation comprising sufentanil and methods of using the same
|
US8518926B2
(en)
*
|
2006-04-10 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Compositions and methods of using (R)-pramipexole
|
WO2007121188A2
(en)
*
|
2006-04-10 |
2007-10-25 |
Knopp Neurosciences, Inc. |
Compositions and methods of using r(+) pramipexole
|
KR20090021169A
(ko)
*
|
2006-05-16 |
2009-02-27 |
크놉 뉴로사이언시스 인코포레이티드 |
R(+) 및 s(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
|
US20070278289A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Toshiba Tec Kabushiki Kaisha |
Payment adjusting apparatus and program therefor
|
KR20150029762A
(ko)
|
2006-06-19 |
2015-03-18 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
CA2671197A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophobic abuse deterrent delivery system
|
DE102006054731B4
(de)
*
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
|
US8524695B2
(en)
*
|
2006-12-14 |
2013-09-03 |
Knopp Neurosciences, Inc. |
Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
|
JP2010521496A
(ja)
|
2007-03-14 |
2010-06-24 |
ノップ ニューロサイエンシーズ、インク. |
キラル精製置換ベンゾチアゾールジアミンの合成
|
AU2008346870A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
EP2259780A2
(en)
*
|
2008-02-28 |
2010-12-15 |
Syntropharma Limited |
Pharmaceutical composition comprising naltrexone
|
US8592424B2
(en)
|
2008-06-30 |
2013-11-26 |
Afgin Pharma Llc |
Topical regional neuro-affective therapy
|
CN105456267A
(zh)
*
|
2008-07-07 |
2016-04-06 |
欧洲凯尔特公司 |
阿片类拮抗剂治疗尿潴留的用途
|
JP2012500283A
(ja)
|
2008-08-19 |
2012-01-05 |
ノップ ニューロサイエンシーズ、インク. |
(r)−プラミペキソールを使用した組成物並びにその方法
|
MY152279A
(en)
|
2009-03-10 |
2014-09-15 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
CN102802418A
(zh)
*
|
2009-06-19 |
2012-11-28 |
诺普神经科学股份有限公司 |
用于治疗肌萎缩性侧索硬化的组合物和方法
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
JP5927506B2
(ja)
|
2010-04-13 |
2016-06-01 |
レルマダ セラピューティクス、インク. |
1−メチル−2’,6’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
RU2586296C2
(ru)
|
2010-07-23 |
2016-06-10 |
Демеркс, Инк. |
Композиции норибогаина
|
AU2011346757B2
(en)
|
2010-12-22 |
2015-08-20 |
Purdue Pharma L.P. |
Encased tamper resistant controlled release dosage forms
|
JP5638151B2
(ja)
|
2010-12-23 |
2014-12-10 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
不正加工抵抗性の(tamperresistant)固形経口剤形
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
ES2842453T3
(es)
*
|
2011-09-05 |
2021-07-14 |
Siegfried Ltd |
Kit que comprende un material de envasado y un producto farmacéutico o nutracéutico sólido contenido en el material de envasado
|
CA2855990A1
(en)
|
2011-12-09 |
2013-06-13 |
Demerx, Inc. |
Sulfate esters of noribogaine
|
CA2855994A1
(en)
|
2011-12-09 |
2013-06-13 |
Demerx, Inc. |
Phosphate esters of noribogaine
|
EA201491164A1
(ru)
|
2011-12-12 |
2014-10-30 |
ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ |
Трансдермальная система доставки
|
WO2013096816A1
(en)
|
2011-12-22 |
2013-06-27 |
Biogen Idec Ma Inc. |
Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
AU2013212139A1
(en)
|
2012-01-25 |
2014-06-26 |
Demerx, Inc. |
Synthetic voacangine
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
WO2014098877A1
(en)
|
2012-12-20 |
2014-06-26 |
Demerx, Inc. |
Substituted noribogaine
|
JP6370802B2
(ja)
|
2012-12-28 |
2018-08-08 |
テイコク ファーマ ユーエスエー インコーポレーテッド |
持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
|
WO2014123899A1
(en)
|
2013-02-05 |
2014-08-14 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US9662313B2
(en)
|
2013-02-28 |
2017-05-30 |
Knopp Biosciences Llc |
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
CA2942638A1
(en)
|
2013-03-15 |
2014-09-18 |
Demerx, Inc. |
Method for noribogaine treatment of addiction in patients on methadone
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
WO2014195352A1
(en)
|
2013-06-04 |
2014-12-11 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal delivery system
|
HUE054185T2
(hu)
|
2013-07-12 |
2021-08-30 |
Knopp Biosciences Llc |
Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
|
US9468630B2
(en)
|
2013-07-12 |
2016-10-18 |
Knopp Biosciences Llc |
Compositions and methods for treating conditions related to increased eosinophils
|
MY183489A
(en)
|
2013-07-23 |
2021-02-22 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
ES2871556T3
(es)
|
2013-08-13 |
2021-10-29 |
Knopp Biosciences Llc |
Composiciones y métodos para el tratamiento de la urticaria crónica
|
ES2813674T3
(es)
|
2013-08-13 |
2021-03-24 |
Knopp Biosciences Llc |
Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
|
US9561232B2
(en)
|
2014-02-18 |
2017-02-07 |
Demerx, Inc. |
Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
|
US9345711B2
(en)
|
2014-02-18 |
2016-05-24 |
Demerx, Inc. |
Methods for acute and long-term treatment of drug addiction
|
US9591978B2
(en)
|
2014-03-13 |
2017-03-14 |
Demerx, Inc. |
Methods and compositions for pre-screening patients for treatment with noribogaine
|
US9561233B2
(en)
|
2014-03-13 |
2017-02-07 |
Demerx, Inc. |
Use of ibogaine for the treatment of pain
|
CA2989550C
(en)
|
2014-06-18 |
2023-08-08 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
US9549935B2
(en)
|
2014-07-14 |
2017-01-24 |
Demerx, Inc. |
Methods and compositions for treating migraines using noribogaine
|
US9592239B2
(en)
|
2014-09-12 |
2017-03-14 |
Demerx, Inc. |
Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
|
CN106794155B
(zh)
*
|
2014-10-14 |
2020-10-30 |
久光制药株式会社 |
贴附剂
|
ES2955490T3
(es)
|
2014-11-26 |
2023-12-01 |
Demerx Inc |
Métodos y composiciones para potenciar la acción de los analgésicos opioides mediante el uso de alcaloides de la iboga
|
WO2016141056A1
(en)
|
2015-03-02 |
2016-09-09 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoids
|
US10383816B2
(en)
|
2015-03-02 |
2019-08-20 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoid combination products
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
US20180049994A1
(en)
|
2016-08-16 |
2018-02-22 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with caryophyllene
|